The change comes ahead of Wednesday’s full-year results, when its injectable HIV drug and Shingrix vaccine will be in focus.
READ: Mixed picture for UK pharma as AstraZeneca ‘top pick’ at Credit Suisse while GSK knocked by Barclays downgrade
The FTSE 100-listed pharma giant had to delay the cabotegravir and rilpivirine HIV treatment due to a late response letter by the US authorities.
Analysts at the investment bank said in a note the product, now expected to be launched in 2021, will be a major part of the ViiV joint venture with minority shareholders Pfizer and Shionogi.
It is set to boost the HIV business, which has seen aq flattening of US sales, to mid-single-digit revenue growth by 2023.
“US script trends for existing drugs in the HIV business indicate continued pressure on Tivicay and Triumeq but steady growth in newer drugs, in line with expectations,” analysts said.
Elsewhere, UBS forecasts £4bn of annual sales by 2026 for Shringrix, a vaccine for shingles.
“We note that management commentary at the start of 2020 refers to a ‘moderate increase’ in supply this year rather than the ‘slightly more doses in 2020’ flagged at the end of 2019,” analysts noted.
Shares were flat at 1,794.2p on Friday morning.